In a Mayo Clinic research study published in the journal Clinical Infectious Diseases, just 4 people out of 483 high-risk clients treated with Paxlovid developed COVID-19 rebound signs.
Mayo Clinic scientists studied the outcomes of treating high-risk patients for COVID-19 with a five-day oral regimen of nirmatrelvir and ritonavir, which are together marketed as Paxlovid. Out of 483 high-risk clients, only a handful developed COVID rebound symptoms, and the researchers say more research is needed to identify why.
In general, the Paxlovid treatment benefited everybody in the research study. All patients recovered, consisting of those who established rebound symptoms, which were usually moderate. The findings were released on June 14, 2022, in the journal Clinical Infectious Diseases.
” We discovered that rebound phenomenon was unusual in this group of patients,” says senior author Aditya Shah, M.B.B.S., a Mayo Clinic transmittable diseases physician and scientist. “The four individuals who experienced rebound (signs) represent just 0.8% of the group, and all of them recovered rapidly without additional COVID-directed treatment.”
Most of the clients in the research study had been immunized, and numerous had gotten booster vaccinations. The average age was 63. While these clients were high-risk for COVID-19, none was immunocompromised. Just two patients were admitted to the hospital, and it was for reasons other than COVID.
The study absolutely nos in on 4 patients with rebound symptoms:
A 75-year-old guy with coronary artery disease who had increased cough and muscle aches 19 days after treatment.
A 69-year-old man with hypertension and weight problems who exhibited nasal discharge and cough 10 days following treatment.
A 40-year-old woman with weight problems, kidney, and hypertension illness who developed tiredness and aching throat six days after treatment.
A 70-year-old male with a history of prostate cancer, obesity, high blood pressure, and high cholesterol, who established substantial sinus blockage 10 days after treatment.
Why did some rebound?
They also note that all 4 clients with rebound signs had numerous serious health problems understood as comorbidities– an aspect understood to make complex recoveries. All 4 patients had been immunized more than 90 days before ending up being infected with COVID-19.
Recommendation: “Rebound Phenomenon after Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease-2019 in High-Risk Persons” by Nischal Ranganath, MD, PhD, John C. OHoro, MD, MPH, Douglas W. Challener, MD, MS, Sidna M. Tulledge-Scheitel, MD, MPH, Marsha L. Pike, APRN, CNS, DNP, R. Michael OBrien, Ph, Raymund R. Razonable, MD, Aditya Shah, MBBS, 14 June 2022, Clinical Infectious Diseases.DOI: 10.1093/ cid/ciac481.
Mayo Clinic funded the study. Others on the study team include very first author Nischal Ranganath M.D., Ph.D.; John OHoro, M.D.; Douglas Challener, M.D.; Sidna Tulledge-Scheitel, M.D.; Marsha Pike, D.N.P.; Michael OBrien; and Raymund Razonable, M.D.– all of Mayo Clinic.
All clients recovered, consisting of those who developed rebound symptoms, which were normally moderate. Many of the patients in the research study had been immunized, and lots of had actually gotten booster vaccinations. While these patients were high-risk for COVID-19, none was immunocompromised. They likewise note that all 4 clients with rebound signs had lots of severe health problems understood as comorbidities– an element understood to make complex healings.